195 related articles for article (PubMed ID: 12542524)
21. Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis.
Pariser DM; Leonardi CL; Gordon K; Gottlieb AB; Tyring S; Papp KA; Li J; Baumgartner SW
J Am Acad Dermatol; 2012 Aug; 67(2):245-56. PubMed ID: 22015149
[TBL] [Abstract][Full Text] [Related]
22. Early and explosive development of nodular basal cell carcinoma and multiple keratoacanthomas in psoriasis patients treated with cyclosporine.
Lain EL; Markus RF
J Drugs Dermatol; 2004; 3(6):680-2. PubMed ID: 15624753
[TBL] [Abstract][Full Text] [Related]
23. Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States.
Kimball AB; Schenfeld J; Accortt NA; Anthony MS; Rothman KJ; Pariser D
Br J Dermatol; 2015 Nov; 173(5):1183-90. PubMed ID: 26265015
[TBL] [Abstract][Full Text] [Related]
24. Risks of cancer associated with long-term exposure to PUVA in humans: current status--1991.
Stern RS
Blood Cells; 1992; 18(1):91-7; discussion 98-9. PubMed ID: 1617196
[TBL] [Abstract][Full Text] [Related]
25. Cyclosporine in the treatment of psoriasis.
Gulliver WP
Cutis; 2000 Nov; 66(5):365-9. PubMed ID: 11107522
[TBL] [Abstract][Full Text] [Related]
26. Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials.
Blauvelt A; Lebwohl M; Langley RG; Rowland K; Yang YW; Chan D; Miller M; You Y; Yu J; Thaҫi D; Foley P; Papp KA
J Am Acad Dermatol; 2023 Aug; 89(2):274-282. PubMed ID: 37019386
[TBL] [Abstract][Full Text] [Related]
27. The Risk of Cancer in Patients With Psoriasis: A Population-Based Cohort Study in the Health Improvement Network.
Chiesa Fuxench ZC; Shin DB; Ogdie Beatty A; Gelfand JM
JAMA Dermatol; 2016 Mar; 152(3):282-90. PubMed ID: 26676102
[TBL] [Abstract][Full Text] [Related]
28. The risk of developing non-melanoma skin cancer, lymphoma and melanoma in patients with psoriasis in Taiwan: a 10-year, population-based cohort study.
Lee MS; Lin RY; Chang YT; Lai MS
Int J Dermatol; 2012 Dec; 51(12):1454-60. PubMed ID: 23171012
[TBL] [Abstract][Full Text] [Related]
29. Increased prevalence of human papillomavirus in hairs plucked from patients with psoriasis treated with psoralen-UV-A.
Wolf P; Seidl H; Bäck B; Binder B; Höfler G; Quehenberger F; Hoffmann C; Kerl H; Stark S; Pfister HJ; Fuchs PG
Arch Dermatol; 2004 Mar; 140(3):317-24. PubMed ID: 15023775
[TBL] [Abstract][Full Text] [Related]
30. Lymphoma risk in psoriasis: results of the PUVA follow-up study.
Stern RS
Arch Dermatol; 2006 Sep; 142(9):1132-5. PubMed ID: 16983000
[TBL] [Abstract][Full Text] [Related]
31. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.
Papp KA; Griffiths CE; Gordon K; Lebwohl M; Szapary PO; Wasfi Y; Chan D; Hsu MC; Ho V; Ghislain PD; Strober B; Reich K; ; ;
Br J Dermatol; 2013 Apr; 168(4):844-54. PubMed ID: 23301632
[TBL] [Abstract][Full Text] [Related]
32. The risk of melanoma and hematologic cancers in patients with psoriasis.
Reddy SP; Martires K; Wu JJ
J Am Acad Dermatol; 2017 Apr; 76(4):639-647.e2. PubMed ID: 27876302
[TBL] [Abstract][Full Text] [Related]
33. Psoriasis and susceptibility to nonmelanoma skin cancer.
Stern RS; Scotto J; Fears TR
J Am Acad Dermatol; 1985 Jan; 12(1 Pt 1):67-73. PubMed ID: 3980806
[TBL] [Abstract][Full Text] [Related]
34. Incidence and Prevalence of Psoriasis in Denmark.
Egeberg A; Skov L; Gislason GH; Thyssen JP; Mallbris L
Acta Derm Venereol; 2017 Jul; 97(7):808-812. PubMed ID: 28417141
[TBL] [Abstract][Full Text] [Related]
35. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden.
Boffetta P; Gridley G; Lindelöf B
J Invest Dermatol; 2001 Dec; 117(6):1531-7. PubMed ID: 11886519
[TBL] [Abstract][Full Text] [Related]
36. Conjunctival squamous cell carcinoma following psoriasis treatment.
Almousa R; Daya S; Lake D; Richardson T; Malhotra R
J Cutan Med Surg; 2012; 16(5):365-7. PubMed ID: 22971315
[TBL] [Abstract][Full Text] [Related]
37. The ultraviolet fingerprint dominates the mutational spectrum of the p53 and Ha-ras genes in psoralen + ultraviolet A keratoses from psoriasis patients.
Wolf P; Kreimer-Erlacher H; Seidl H; Bäck B; Soyer HP; Kerl H
J Invest Dermatol; 2004 Jan; 122(1):190-200. PubMed ID: 14962108
[TBL] [Abstract][Full Text] [Related]
38. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up.
Reich K; Papp KA; Griffiths CE; Szapary PO; Yeilding N; Wasfi Y; Ott E; Hsu MC; Lebwohl M; Gordon KB;
J Drugs Dermatol; 2012 Mar; 11(3):300-12. PubMed ID: 22395580
[TBL] [Abstract][Full Text] [Related]
39. De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients.
Gruber SA; Gillingham K; Sothern RB; Stephanian E; Matas AJ; Dunn DL
Clin Transplant; 1994 Aug; 8(4):388-95. PubMed ID: 7949545
[TBL] [Abstract][Full Text] [Related]
40. Adverse events from systemic therapies for psoriasis are common in clinical practice.
Pearce DJ; Higgins KB; Stealey KH; Balkrishnan R; Crane MM; Camacho F; Fleischer AB; Feldman SR
J Dermatolog Treat; 2006; 17(5):288-93. PubMed ID: 17092859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
